beginner12 min read

The FDA Approval Process Explained

Reviewed by Blane Jackson, DDS, MBA. Educational guide only. See the editorial policy and disclosures.

If you're investing in biotech, understanding how the FDA approves drugs is like knowing the rules of the game. It's the single most important factor that determines whether a small biotech becomes a giant or goes bust. In this guide, we'll walk you through the step-by-step journey of a drug from lab bench to pharmacy shelf, demystify the jargon, and show you what each stage means for your investments. By the end, you'll know what to look for when a company announces a 'Phase 3 success' or an 'FDA submission' – and you'll be able to spot the risks and opportunities that others miss.

The Big Picture: Why FDA Approval Matters

The FDA (Food and Drug Administration) is the US government agency that decides whether new drugs are safe and effective enough to be sold to Americans. No approval, no market – it's that simple. For investors, FDA approval is the ultimate catalyst: it can turn a speculative penny stock into a profitable company overnight. But the road to approval is long, expensive, and fraught with failure. On average, it takes 10-15 years and over $1 billion to bring a new drug to market, and only about 12% of drugs that enter clinical trials ever get approved. That's why biotech stocks are so volatile – every milestone (or setback) can swing the stock price dramatically. Understanding the process helps you anticipate these swings and make smarter investment decisions.

Key takeaway

FDA approval is the gatekeeper to the US market – without it, a drug cannot be sold, and for investors, it's the biggest value-creating event in a biotech's lifecycle.

Example

In 2020, when Pfizer and BioNTech announced their COVID-19 vaccine was over 90% effective, BioNTech's stock soared. But the real jump came when the FDA granted Emergency Use Authorization – that's when the stock became a household name.

Preclinical Research: The Starting Line

Before a drug is ever tested in humans, it goes through years of preclinical research. Scientists test the drug in test tubes and in animals (like mice or monkeys) to answer two basic questions: Is it safe? Does it work? This stage is called 'preclinical' because it happens before clinical trials (human testing). Companies often spend years here, tweaking the molecule to improve its chances. For investors, preclinical data is early-stage and highly speculative – many drugs fail here. But if a company announces positive preclinical results, it can be a speculative catalyst, especially for small caps. However, don't get too excited: the FDA requires an Investigational New Drug (IND) application before human trials can begin, and that's a major hurdle.

Key takeaway

Preclinical success is promising but far from proof – most drugs fail in human trials, so treat preclinical announcements as high-risk speculation.

Example

In 2021, a small biotech called Cassava Sciences reported positive preclinical data for its Alzheimer's drug, sending its stock up over 200%. But later, questions about data integrity caused the stock to crash – a cautionary tale about overreacting to early data.

Ready to start? Open a Webull account and trade biotech stocks commission-freevia Webull · Affiliate

Clinical Trials: Phase 1, 2, and 3

Once the FDA approves an IND, the drug enters clinical trials, which are conducted in three main phases. Phase 1 involves a small group (20-80) of healthy volunteers or patients, and focuses on safety: How is the drug metabolized? What's the maximum tolerated dose? Phase 2 expands to a few hundred patients to get an initial read on effectiveness and further safety. Phase 3 is the big one: thousands of patients, often in a randomized, placebo-controlled trial, to confirm efficacy and monitor side effects. For investors, Phase 2 and Phase 3 results are major catalysts. A successful Phase 3 trial is often the strongest signal that a drug might get approved. But beware: even Phase 3 trials can fail, and the FDA may still reject the drug if safety issues arise.

Key takeaway

Phase 3 is the make-or-break moment – a positive Phase 3 result dramatically increases the odds of approval, but it's not a guarantee.

Example

In 2021, Biogen's Alzheimer's drug aducanumab (Aduhelm) passed Phase 3, but the FDA's approval was controversial because the data was mixed. The stock initially surged, then fell as doctors and insurers refused to use the drug.

The New Drug Application (NDA) and FDA Review

After a successful Phase 3 trial, the company compiles all its data into a New Drug Application (NDA) – a massive document that can be hundreds of thousands of pages. The FDA then has 60 days to decide whether to accept the application for review. If accepted, the FDA has a goal of reviewing the drug within 10 months (or 6 months for priority review). During this time, the FDA convenes an advisory committee of outside experts to vote on whether the drug should be approved. While not binding, the FDA usually follows the committee's recommendation. For investors, the NDA acceptance and the advisory committee meeting are key catalysts. The FDA's decision date is called a PDUFA date – the day the FDA will announce its final decision. If approved, the drug can be marketed; if not, the company may need to conduct more trials.

Key takeaway

The FDA review period is a nail-biter for investors – watch for advisory committee votes and PDUFA dates, as they can cause huge stock swings.

Example

In 2022, the FDA was set to decide on a new ALS drug from Amylyx Pharmaceuticals. The advisory committee voted 7-2 in favor, and the FDA approved it – Amylyx's stock jumped over 40% on the news.

Post-Approval: Phase 4 and Beyond

Approval isn't the end of the story. The FDA often requires post-marketing studies, known as Phase 4 trials, to monitor long-term safety and effectiveness. The drug also has to be manufactured to strict standards, and the company must report any adverse events. For investors, approval is a major milestone, but it doesn't mean the stock will keep rising. The commercial success depends on factors like pricing, competition, and market adoption. Some drugs become blockbusters, while others flop. Also, the FDA can withdraw approval if new safety issues arise. So, even after approval, there are risks.

Key takeaway

Approval is a new beginning – the real investment thesis shifts to commercial execution and long-term safety monitoring.

Example

After Vioxx was approved, it became a blockbuster painkiller for Merck, but it was withdrawn from the market in 2004 due to heart attack risks – a reminder that post-approval safety is critical.

Key terms

FDA

The US Food and Drug Administration, the federal agency responsible for protecting public health by ensuring the safety and efficacy of drugs, vaccines, and medical devices.

Preclinical

The stage of drug development before human testing, involving laboratory and animal studies to assess safety and biological activity.

IND

Investigational New Drug application – a request to the FDA to allow human testing of an experimental drug.

Clinical Trial

A research study conducted in humans to evaluate a drug's safety and effectiveness. Divided into phases (1, 2, 3, 4).

Phase 1

The first human trials, typically involving 20-80 healthy volunteers, focused on safety and dosage.

Phase 2

Trials in a few hundred patients to gather initial efficacy data and further assess safety.

Phase 3

Large-scale trials in thousands of patients to confirm efficacy and monitor side effects – the pivotal trials for approval.

NDA

New Drug Application – the formal request to the FDA for approval to market a new drug in the US.

Advisory Committee

A panel of independent experts that reviews drug data and votes on whether to recommend FDA approval. The FDA often follows their advice.

PDUFA Date

The date by which the FDA must make a decision on a drug application. Named after the Prescription Drug User Fee Act.

Phase 4

Post-approval studies conducted to gather additional information on long-term safety and effectiveness.

Next steps

When a biotech announces Phase 3 results, check if the trial met its primary endpoint and look for any safety red flags before getting excited.

Track upcoming PDUFA dates for drugs you're interested in – these are major catalysts that can cause big stock moves.

Before investing, read the FDA's briefing documents for advisory committee meetings – they contain detailed analyses and often hint at the FDA's stance.

Diversify your biotech portfolio across different stages of development to manage risk – don't put all your money in one Phase 3 stock.

After approval, watch for commercial launch metrics like prescription numbers and revenue – these will determine if the stock continues to rise.

Put this guide to work

Use these free ClinicalInvestor tools to apply what you just learned.

2026 PDUFA Calendar →

Every FDA decision in 2026 with AI investor analysis.

Biotech Catalyst Calendar →

PDUFA dates, Phase 3 readouts, AdComs, and conferences. Free.

Trial Translator →

Paste any ClinicalTrials.gov ID and get a plain-English AI breakdown.

Biotech Screener →

Filter published biotech profiles by area, phase, market cap, and runway.

Company Profiles →

Pipelines, bull and bear cases, and next expected data for every covered biotech.

Keep learning

PDUFA Dates Explained →Clinical Trial Phases Explained →How to Read Clinical Trial Data →Biotech Stock Catalysts Guide →How to Invest in Biotech Stocks →